Pearson G D, Veille J C, Rahimtoola S, Hsia J, Oakley C M, Hosenpud J D, Ansari A, Baughman K L
Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892-7940, USA.
JAMA. 2000 Mar 1;283(9):1183-8. doi: 10.1001/jama.283.9.1183.
Peripartum cardiomyopathy (PPCM) is a rare life-threatening cardiomyopathy of unknown cause that occurs in the peripartum period in previously healthy women. In April 1997, the National Heart, Lung, and Blood Institute (NHLBI) and the Office of Rare Diseases of the National Institutes of Health (NIH) convened a Workshop on Peripartum Cardiomyopathy to foster a systematic review of information and to develop recommendations for research and education.
Fourteen workshop participants were selected by NHLBI staff and represented cardiovascular medicine, obstetrics, immunology, and pathology. A representative subgroup of 8 participants and NHLBI staff formed the writing group for this article and updated the literature on which the conclusions were based. The workshop was an open meeting, consistent with NIH policy.
Data presented at the workshop were augmented by a MEDLINE search for English-language articles published from 1966 to July 1999, using the terms peripartum cardiomyopathy, cardiomyopathy, and pregnancy. Articles on the epidemiology, pathogenesis, pathophysiology, diagnosis, treatment, and prognosis of PPCM were included. RECOMMENDATION PROCESS: After discussion of data presented, workshop participants agreed on a standardized definition of PPCM, a general clinical approach, and the need for a registry to provide an infrastructure for future research.
Peripartum cardiomyopathy is a rare lethal disease about which little is known. Diagnosis is confined to a narrow period and requires echocardiographic evidence of left ventricular systolic dysfunction. Symptomatic patients should receive standard therapy for heart failure, managed by a multidisciplinary team. If subsequent pregnancies occur, they should be managed in collaboration with a high-risk perinatal center. Systematic data collection is required to answer important questions about incidence, treatment, and prognosis.
围产期心肌病(PPCM)是一种罕见的、危及生命的、病因不明的心肌病,发生于既往健康的女性围产期。1997年4月,美国国立心肺血液研究所(NHLBI)和美国国立卫生研究院(NIH)罕见病办公室召开了一次围产期心肌病研讨会,以促进对信息的系统回顾,并制定研究和教育建议。
NHLBI工作人员挑选了14名研讨会参与者,他们代表心血管医学、产科、免疫学和病理学领域。8名参与者和NHLBI工作人员组成的代表性小组为此文的撰写小组,并更新了作为结论依据的文献。该研讨会是一次公开会议,符合NIH的政策。
通过MEDLINE检索1966年至1999年7月发表的英文文章,使用围产期心肌病、心肌病和妊娠等关键词,对研讨会上展示的数据进行补充。纳入了关于PPCM的流行病学、发病机制、病理生理学、诊断、治疗和预后的文章。
在讨论所展示的数据后,研讨会参与者就PPCM的标准化定义、一般临床方法以及建立一个登记处为未来研究提供基础设施的必要性达成了一致。
围产期心肌病是一种罕见的致命疾病,人们对此知之甚少。诊断限于一个狭窄的时间段,需要超声心动图证据证明左心室收缩功能障碍。有症状的患者应接受心力衰竭的标准治疗,由多学科团队管理。如果随后发生妊娠,应与高危围产期中心合作进行管理。需要进行系统的数据收集,以回答有关发病率、治疗和预后的重要问题。